ATE401309T1 - Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen - Google Patents

Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen

Info

Publication number
ATE401309T1
ATE401309T1 AT05016160T AT05016160T ATE401309T1 AT E401309 T1 ATE401309 T1 AT E401309T1 AT 05016160 T AT05016160 T AT 05016160T AT 05016160 T AT05016160 T AT 05016160T AT E401309 T1 ATE401309 T1 AT E401309T1
Authority
AT
Austria
Prior art keywords
fuoro
onenes
aupyrimidine
tetrahydro
produce
Prior art date
Application number
AT05016160T
Other languages
English (en)
Inventor
Thierry Gallet
Patrick Lardenois
Alistair Lochead
Severine Marguerie
Alain Nedelec
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01402432A external-priority patent/EP1295885A1/de
Priority claimed from EP02290489A external-priority patent/EP1340761A1/de
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE401309T1 publication Critical patent/ATE401309T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pest Control & Pesticides (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
AT05016160T 2001-09-21 2002-09-19 Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen ATE401309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402432A EP1295885A1 (de) 2001-09-21 2001-09-21 Substituierte 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)onderivate
EP02290489A EP1340761A1 (de) 2002-02-28 2002-02-28 Substituierte 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate

Publications (1)

Publication Number Publication Date
ATE401309T1 true ATE401309T1 (de) 2008-08-15

Family

ID=26077256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05016160T ATE401309T1 (de) 2001-09-21 2002-09-19 Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
AT02785157T ATE303388T1 (de) 2001-09-21 2002-09-19 Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02785157T ATE303388T1 (de) 2001-09-21 2002-09-19 Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate

Country Status (24)

Country Link
US (2) US7214682B2 (de)
EP (2) EP1430057B1 (de)
JP (3) JP4570362B2 (de)
KR (1) KR100868841B1 (de)
CN (2) CN1247585C (de)
AR (1) AR036600A1 (de)
AT (2) ATE401309T1 (de)
AU (1) AU2002350487C1 (de)
BR (1) BR0212896A (de)
CA (1) CA2457965C (de)
CY (1) CY1108341T1 (de)
DE (2) DE60227718D1 (de)
DK (2) DK1430057T3 (de)
EA (1) EA006859B1 (de)
ES (2) ES2247398T3 (de)
HU (1) HUP0500328A3 (de)
IL (2) IL160402A0 (de)
MX (1) MXPA04002629A (de)
NO (1) NO329565B1 (de)
NZ (2) NZ531243A (de)
PL (1) PL370349A1 (de)
PT (1) PT1674456E (de)
SI (1) SI1430057T1 (de)
WO (1) WO2003027116A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531243A (en) * 2001-09-21 2006-08-31 Sanofi Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)one derivatives
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
EP1454909B1 (de) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one und 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one Derivate und deren Benutzung gegen neurodegenerative Krankheiten
EP1454900A1 (de) * 2003-03-07 2004-09-08 Sanofi-Synthelabo Verfahren zur herstellung von pyridinyl und pyrimidinyl mono-fluorierten beta-keto Estern
EP1557417B1 (de) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituierte 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one Derivate
WO2005070932A2 (en) 2004-01-22 2005-08-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101735211B (zh) * 2008-11-04 2012-11-14 复旦大学 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
HUE034503T2 (en) 2009-07-02 2018-02-28 Sanofi Sa 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
ES2487623T3 (es) * 2009-07-02 2014-08-22 Sanofi Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
CN114957246B (zh) * 2021-02-19 2025-11-11 苏州恩华生物医药科技有限公司 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4（3H）-酮衍生物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
BR9713863A (pt) 1996-12-05 2000-03-14 Amgen Inc Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
JP2000264888A (ja) * 1999-01-11 2000-09-26 Sagami Chem Res Center 双環性ピリミジン誘導体、それらの製造中間体及びそれらの製造方法、並びにそれらを有効成分とする除草剤
UA67832C2 (uk) * 1999-03-22 2004-07-15 Орто-Макнейл Фармацевтикал, Інк. СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ
WO2001042224A1 (en) * 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
EP1240168B1 (de) 1999-12-17 2005-08-31 Chiron Corporation Bizyklische inhibitoren von glycogen synthase kinase 3
CN100339379C (zh) * 2000-09-01 2007-09-26 圣诺菲-合成实验室公司 2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－а]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－а]嘧啶－5（1H）酮衍生物
NZ531243A (en) * 2001-09-21 2006-08-31 Sanofi Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)one derivatives

Also Published As

Publication number Publication date
CA2457965A1 (en) 2003-04-03
DE60205921D1 (de) 2005-10-06
HK1091208A1 (zh) 2007-01-12
EP1430057B1 (de) 2005-08-31
DK1674456T3 (da) 2008-10-27
JP4570362B2 (ja) 2010-10-27
HUP0500328A2 (hu) 2005-07-28
JP2005504810A (ja) 2005-02-17
DK1430057T3 (da) 2006-01-16
CA2457965C (en) 2010-06-01
PL370349A1 (en) 2005-05-16
KR20040029486A (ko) 2004-04-06
AU2002350487C1 (en) 2008-10-02
CY1108341T1 (el) 2014-02-12
SI1430057T1 (sl) 2006-02-28
EP1674456B1 (de) 2008-07-16
CN1817884A (zh) 2006-08-16
MXPA04002629A (es) 2005-02-17
CN1556809A (zh) 2004-12-22
NZ531243A (en) 2006-08-31
BR0212896A (pt) 2004-10-13
ES2310787T3 (es) 2009-01-16
JP2010209089A (ja) 2010-09-24
US7214682B2 (en) 2007-05-08
PT1674456E (pt) 2008-09-11
AU2002350487B2 (en) 2008-01-31
KR100868841B1 (ko) 2008-11-14
EP1674456A2 (de) 2006-06-28
NO329565B1 (no) 2010-11-15
DE60205921T2 (de) 2006-06-22
CN1247585C (zh) 2006-03-29
ATE303388T1 (de) 2005-09-15
CN100398541C (zh) 2008-07-02
US20070167461A1 (en) 2007-07-19
EP1430057A2 (de) 2004-06-23
US7462621B2 (en) 2008-12-09
WO2003027116A3 (en) 2003-08-28
ES2247398T3 (es) 2006-03-01
US20050049261A1 (en) 2005-03-03
AR036600A1 (es) 2004-09-22
DE60227718D1 (de) 2008-08-28
IL160402A0 (en) 2004-07-25
HUP0500328A3 (en) 2009-12-28
EA200400237A1 (ru) 2004-10-28
IL160402A (en) 2008-08-07
JP2010159303A (ja) 2010-07-22
WO2003027116A2 (en) 2003-04-03
EP1674456A3 (de) 2006-07-05
NO20041141L (no) 2004-06-21
EA006859B1 (ru) 2006-04-28
NZ547205A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
ATE401309T1 (de) Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
DE60137039D1 (de) Verschiebung von verschlüssen zur herstellung von windeln
DE60222644D1 (de) Prozess zur herstellung von transparenten formteilen
DE502004001052D1 (de) Verwendung von polysilazan zur herstellung von hydrophob- und oleophobmodifizierten oberflächen
DE60134410D1 (de) Methode zur herstellung funktioneller proteindomänen
DE60116815D1 (de) Färbestruktur zur Herstellung von Farbe
DE60106932D1 (de) Verfahren zur herstellung von citalopram
DE50100948D1 (de) Herstellung von Organosilanen
DE60201498D1 (de) Verbesserter prozess zur herstellung von carbapenemen
ATE546425T1 (de) Herstellung von (r)-2-alkyl-3-phenylpropionsäuren
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60211632D1 (de) Verwendung von Cyclotetrasaccharide zur Erhöhung der &#34;Aktiven-Sauerstoff-Eliminierenden-Aktivität&#34;
DE60208738D1 (de) Verfahren zur Herstellung von Chlorfluorpolyoxyalkylenolen
DE60100858D1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
DE60201084D1 (de) Herstellung von cyclischen esteroligomeren
DE60110200D1 (de) Verfahren zur Herstellung von Prepregs
ATE343605T1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60142051D1 (de) Herstellung von perfluorolefinen
ATE359285T1 (de) Verwendung von scopinester derivaten zur herstellung von arzneimitteln
DE60028816D1 (de) Herstellung von unipolaren Komponenten
DE60133280D1 (de) Verfahren zur herstellung von citalopram
DE10294286D2 (de) Herstellung von trägergebundenen Molekülen
DE60113157D1 (de) Verbessertes verfahren zur herstellung von simvastatin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1674456

Country of ref document: EP